Jérôme Cros
YOU?
Author Swipe
View article: Molecular alterations in high‐grade neuroendocrine tumors of the small intestine
Molecular alterations in high‐grade neuroendocrine tumors of the small intestine Open
High‐grade neuroendocrine tumors of the small intestine are separated into two groups: well‐differentiated neuroendocrine tumors (NETs, high‐grade) and poorly differentiated neuroendocrine carcinomas (NECs). They represent very rare entiti…
View article: Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients
Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients Open
Background: In non-metastatic pancreatic adenocarcinoma (PDAC), the appropriate evaluation of tumor response to neoadjuvant treatment (NAT) has a substantial prognostic impact, but the tools used to assess it are imperfect and sometimes di…
View article: Self-supervised learning to predict intrahepatic cholangiocarcinoma transcriptomic classes on routine histology
Self-supervised learning to predict intrahepatic cholangiocarcinoma transcriptomic classes on routine histology Open
Background & Aims: The transcriptomic classification of intrahepatic cholangiocarcinoma (iCCA) has recently been refined from two to five classes, each associated with pathological features, targetable genetic alterations, and survival out…
View article: Characteristics of <i>KRAS</i> WT pancreatic adenocarcinomas: results of a large French multicentric cohort
Characteristics of <i>KRAS</i> WT pancreatic adenocarcinomas: results of a large French multicentric cohort Open
Background: Genome and transcriptome analysis has enhanced the characterisation of pancreatic ductal adenocarcinoma (PDAC), paving the way for targeted therapies. Tumours KRAS wild type (WT) represent a unique subgroup. Objectives: Charact…
View article: FedECA: federated external control arms for causal inference with time-to-event data in distributed settings
FedECA: federated external control arms for causal inference with time-to-event data in distributed settings Open
External control arms can inform early clinical development of experimental drugs and provide efficacy evidence for regulatory approval. However, accessing sufficient real-world or historical clinical trials data is challenging. Indeed, re…
View article: White paper on best practices for translational research in neuroendocrine neoplasms
White paper on best practices for translational research in neuroendocrine neoplasms Open
Basic and translational investigations play a crucial role in advancing our understanding of neuroendocrine neoplasms (NENs). In this white paper by the Basic and Translational Research Group of the European Neuroendocrine Tumor Society, w…
View article: Glycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer
Glycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer Open
BACKGROUND & AIMS Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited response to systemic therapy. Gemcitabine (GEM) benefits only a subset of patients. Methylglyoxal (MG), a glycolysis byproduct, has been linke…
View article: Medical management of pancreatic cancer: from personalization to broadening treatment strategies
Medical management of pancreatic cancer: from personalization to broadening treatment strategies Open
Pancreatic ductal adenocarcinoma (PDAC) is one of the most heterogeneous and deadly cancers. This review examines recently implemented strategies to integrate predictive tools and targeted therapies to improve treatments personalization an…
View article: Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome
Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome Open
We identified a new stakeholder, PAPPA-2, known to modulate IGF bioavailability, as playing a possible role in GLP-2 mechanism of action in human with SBS. We showed by association the existence of a greater spontaneous intestinal adaptati…
View article: Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study
Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study Open
Background: Advanced pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis with a 5-year survival rate of 3%. While treated as an even population, previous retrospective studies suggested significantly different survival rates…
View article: Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom‐up approach
Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom‐up approach Open
Pancreatic ductal adenocarcinoma (PDAC) tumor interpatient heterogeneity has been well described with two major prognostic subtypes (classical and basal‐like). An important intrapatient heterogeneity has been reported but has not yet been …
View article: Mural nodules and prevalence of high-grade dysplasia in branch duct intraductal papillary mucinous neoplasm of the pancreas undergoing resection
Mural nodules and prevalence of high-grade dysplasia in branch duct intraductal papillary mucinous neoplasm of the pancreas undergoing resection Open
Background A mural module (MN) within a branch-duct intraductal papillary mucinous neoplasm (BD-IPMN) could be a potential target for local treatment. The main aim was to describe the location of the highest grade of dysplasia relative to …
View article: FedECA: A Federated External Control Arm Method for Causal Inference with Time-To-Event Data in Distributed Settings
FedECA: A Federated External Control Arm Method for Causal Inference with Time-To-Event Data in Distributed Settings Open
External control arms (ECA) can inform the early clinical development of experimental drugs and provide efficacy evidence for regulatory approval. However, the main challenge in implementing ECA lies in accessing real-world or historical c…
View article: A robust workflow to benchmark deconvolution of multi-omic data
A robust workflow to benchmark deconvolution of multi-omic data Open
Tumour heterogeneity significantly affects cancer progression and therapeutic response, yet quantifying it from bulk molecular data remains challenging. Deconvolution algorithms, which estimate cell-type proportions in bulk samples, offer …
View article: Clearance of pathogenic erythrocytes is maintained despite spleen dysfunction in children with sickle cell disease
Clearance of pathogenic erythrocytes is maintained despite spleen dysfunction in children with sickle cell disease Open
In children with sickle cell disease (SCD), splenectomy is immediately beneficial for acute sequestration crises and hypersplenism (ASSC/HyS) but portends a long‐term risk of asplenia‐related complications. We retrieved peripheral and sple…
View article: Measurement and comparison of dielectric properties of human pancreatic tumours, healthy tissues and porcine tissues ex vivo between 1Hz and 1MHz
Measurement and comparison of dielectric properties of human pancreatic tumours, healthy tissues and porcine tissues ex vivo between 1Hz and 1MHz Open
The dielectric properties of pancreatic tissues from human healthy and tumour-bearing tissues have been extracted from impedance measurement on ex vivo, freshly excised samples. They are compared to pig pancreas samples, measured following…
View article: Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma Open
This study presents a transcriptome-based tool that was developed using preclinical models and machine learning to accurately predict sensitivity to mFFX and GEM.
View article: Ampullary tumors: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR)
Ampullary tumors: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR) Open
These guidelines help to homogenize and highlight unmet needs in the management of AA and AC. Each individual case should be discussed by a multidisciplinary team.
View article: Self-supervised learning to predict intrahepatic cholangiocarcinoma transcriptomic classes on routine histology
Self-supervised learning to predict intrahepatic cholangiocarcinoma transcriptomic classes on routine histology Open
Objective The transcriptomic classification of intrahepatic cholangiocarcinomas (iCCA) has been recently refined from two to five classes, associated with pathological features, targetable genetic alterations and survival. Despite its prog…
View article: Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach
Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach Open
Background Pancreatic ductal adenocarcinoma (PDAC) tumor inter-patient heterogeneity has been well described with two major prognostic subtypes (classical and basal-like). An important intra-patient heterogeneity has been reported but has …
View article: Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial Open
PURPOSE GemPred, a transcriptomic signature predictive of the efficacy of adjuvant gemcitabine (GEM), was developed from cell lines and organoids and validated retrospectively. The phase III PRODIGE-24/CCTG PA6 trial has demonstrated the s…